Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAA-Specific CTLs for Solid Tumors
NCT02239861Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Apr 2015
- Primary completion
- Oct 2018
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAA-CTL in solid tumor, sponsored by Baylor College of Medicine. Primary endpoint: Dose-Limiting Toxicity at 8 weeks. Started Apr 2015; status: completed.
02
Drugs
TAA-CTL
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02239861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239861.